FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
via HealthDayTHURSDAY, March 26, 2026 — The U.S. Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer.
The agency sent a warning letter Tuesday to ImmunityBio, saying recent statements about its drug Anktiva were misleading.
The concerns involve comments made by its billionaire chairman, Dr. Patrick Soon-Shiong, during a January episode of "The Sean Spicer Show" podcast.
During the interview, Soon-Shiong, who also owns the Los Angeles Times, described the drug as "the most important molecule that could cure cancer." He also said that while Anktiva is approved for bladder cancer, "it actually can treat all cancers," The Associated Press reported.
At another point, he said, “We have the therapy to prevent cancer if you were exposed to radiation, and that’s Anktiva.”
FDA officials said those statements break federal marketing rules, because they “create a misleading impression” about what the drug can do.
Anktiva was approved in 2024 for patients with a hard-to-treat type of bladder cancer.
The company has been working to expand approval of the drug for other cancers, including lung and pancreatic cancer. But the FDA has not approved those uses.
Regulators also raised concerns about a TV ad and the podcast promo, both of which described the drug as a "cancer vaccine." The FDA said that claim is false.
The agency also noted that the podcast did not mention possible risks or side effects, which is required in drug promotion.
Side effects of the drug can include urinary tract infections, pain, chills and fever.
The FDA gave ImmunityBio 15 days to respond and explain how it will fix the issues, The Associated Press said.
A spokesperson for the company said it takes the warning “very seriously” and plans to “work cooperatively with the agency to address the matters raised in the letter.”
By Tuesday afternoon, the podcast link had been removed from ImmunityBio’s website.
The FDA has recently increased its review of drug promotions, including claims made by company leaders in interviews, TV appearances and podcasts.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-27 02:00
Read more
- Online Tool Enables Communication of Genetic Testing Results With Family Members
- Norovirus Sickens Close to 200 People on Caribbean Cruise
- Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- Lawsuit Over Viral David Protein Bars Dropped Without Explanation
- Study Links High Antioxidant Intake To Changes in Offspring Development
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions